The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Kailos Genetics sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Kailos Genetics is a genetic sequencing company. It provides novel genetic sequencing solutions to empower physicians and their patients by making precision medicine possible. The company’s proprietary sequencing workflow technology, Kailos targets relevant genomic regions to equip clinicians with actionable and up-to-date genetic information. The company’s Expedio Hereditary Cancer and Inspexion Pharmacogenomics tests are physician-directed genetic screenings that offer a cost-effective strategy designed to achieve optimized, personalized care for patients. Kailos Genetics precision medicine tests utilize DNA sequencing to customize healthcare for all patients. Its laboratory is located on the campus of the prestigious HudsonAlpha Institute for Biotechnology in Huntsville. Kailos Genetic is headquartered in Huntsville, Alabama, the US.
The key metrics of Kailos Genetics related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Kailos Genetics is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Kailos Genetics.
For a detailed understanding of the performance of Kailos Genetics, buy the report here.